In today’s Pharmaceutical Executive Daily, Hims & Hers withdraws access to its compounded semaglutide pill following a controversy filled launch, next-generation trial designs increasingly integrate ...

Yerem Yeghiazarians founder and CEO of Soley Therapetuics touches on how Soley's approach reverses traditional drug development and reduces failure risks.

Novo Nordisk, the manufacturer of Wegovy, responded strongly to the initial launch of Hims & Hers’ compounded semaglutide ...

Eli Lilly reinforced its push into next-generation immunology and oncology innovation through two major transactions: the planned acquisition of Orna Therapeutics and a new large-scale strategic ...

Real-world data (RWD) is transforming clinical research, augmenting existing randomized controlled trial (RCT) data to de-risk studies and improve generalizability. With regulators setting clearer ...

Lou Pillai is the founder of Ulivmo and most recently, he was the Head of Data and Digital at Immunomedics (acquired by Gilead). Ehsan Ehsani is a director of consulting at CGI and leader of ...

In today’s Pharmaceutical Executive Daily, TrumpRx officially launches, the FDA moves against mass marketing of illegal copycat drugs, and AI emerges as a force multiplier for small and mid-size ...

Novo Nordisk is debuting its first-Super Bowl commercial to promote its newly launched once-daily Wegovy pill, an oral formulation of semaglutide for adults with obesity or overweight with related ...

President Trump first announced TrumpRx in September, 2025. The announcement came after a period of negotiations with major pharma companies to reduce drug costs in the United States.

In his post, Makary said, “FDA will take swift action against companies’ mass-marketing illegal copycat drugs, claiming they ...

In a lean biotech environment with aggressive milestones, teams often accept reporting that is “good enough.” But those ...

After months of speculation, TrumpRx is live and offering Americans a variety of important medications at most-favored-nation ...